Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Sino Biopharmaceutical (01177.HK) Subsidiary Unveils Data on Two Self-Developed ADCs at American Association for Cancer Research
Recommend 3 Positive 5 Negative 3 |
||||
|
||||
|
Sino Biopharmaceutical (01177.HK) announced that its wholly owned subsidiary, LaNova Medicines, presented the latest research data on two self-developed next-generation antibody-drug conjugates (ADCs), LM-364 "Nectin-4TME ADC" and LM-338 "STn ADC", at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). LM-364 is a next-generation Nectin-4TME ADC developed by LaNova Medicines based on its proprietary tumor microenvironment (TME) platform. The molecule adopts an adenosine nucleotide phosphate (ANP)-dependent binding mechanism. As ANP concentration in the tumor microenvironment (micromolar level) is significantly higher than that in normal tissues (nanomolar level), LM-364 can achieve conditionally high-affinity activation at tumor sites, thereby enhancing drug internalization and toxin release while significantly reducing off-target toxicity in normal tissues. This approach provides a new pathway to address long-standing safety challenges in the ADC field. Nectin-4, a clinically validated target, is highly expressed in multiple solid tumors, including urothelial carcinoma and triple-negative breast cancer. However, a key bottleneck in its clinical development lies in the low-level expression of the target in normal tissues, which may lead to dose-limiting toxicities such as rash and neurotoxicity. Currently, LM-364 has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with plans to initiate its first-in-human (FIH) clinical trial in 2026. (jl/w) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
